|Day Low/High||42.41 / 42.41|
|52 Wk Low/High||41.45 / 52.40|
LONDON, May 2, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational generic pharmaceutical company, today announced that it will serve as a Gold Sponsor of the Massachusetts Institute of...
LONDON, May 1, 2019 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) the multinational pharmaceutical company, today launched its 100 th injectable medicine in...
Hikma Pharmaceuticals USA Inc., a wholly owned subsidiary of Hikma Pharmaceuticals PLC ("Hikma") (LSE:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY), the multinational generic pharmaceutical company, will demonstrate its commitment to serving the needs of US...
Hikma Pharmaceuticals PLC (the Hikma Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the multinational generic pharmaceutical company, announced today that its US business has begun releasing significant quantities of hydromorphone to US hospital...
Fed confusion and the 'Game of Thrones' in the White House dragged markets lower.
Hikma lowered its guidance and failed to concerns over Advair generic
Earnings also sent some stocks into a spiral
The rescue of two failing Italian lenders helped to lift European benchmarks higher Monday, with solid gains for lenders in Southern Europe in particular.
Hikma shares were active in London trading Monday after the drugmaker unveiled a reorganization of its U.S. business that includes a change in leadership.
European stocks rebounded Friday as investors shook off the pessimism of recent days, with price action supported by both M&A as well as corporate earnings news.
European stocks rose firmly higher in the opening hour of trading Friday as global financial markets attempted to claw back losses from a volatile week of trading.
Hikma Pharmaceuticals lowered its full year revenue guidance Friday after the U.S. Food & Drug Administration expressed concern over its generic Advair Diskus product.
European stocks slumped Wednesday as the latest skirmish in Washington, over President Donald Trump's unorthodox stewardship of the Oval Office left markets jilted.
Hikma could get hit with sizeable downgrades Friday when it updates the market with new guidance in the wake of the FDA's rejection of its generic Advair Diskus product
Most major benchmarks were down Thursday, with Madrid and Frankfurt the deepest in the red, while London bucked the trend thanks to a weaker sterling
Hikma shares plunged the most in nine months inLondon trading Thursday after the drugmaker said that approval of its generic Advair Diskus asthma treatment faces delays from the FDA.
European stock markets were mixed Wednesday's as investors responded to yet another raft earnings reports, company statements and comments from policy makers across the continent.
Hikma Pharmaceuticals fell sharply in London ahead of a crucial decision by the U.S. Food & Drug Administration on whether to approve its generic Advair asthma treatment.
From automakers to financials, strong corporate earnings numbers helped to boost major European benchmarks Wednesday, although stocks in Southern Europe fell on concerns over bank capital
Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017
M&A, French election relief and renewed talk of reforms to taxes and trade all helped to push European stocks higher Tuesday
Markets were buoyant throughout much of the session but turned sharply lower after terror struck the subway system in St Petersburg
Unease over the outlook for global trade, monetary policies and politica stability torpedoed markets from early on Tuesday
A rebound in commodities and expectations of a Fed rate hike helped to drive markets higher
European stocks held onto modest gains Wednesday as investors set positions ahead of a key rate decision from the U.S. Federal Reserve and results from national elections in the Netherlands.
Hikma Pharmaceuticals shares surged to a seven-month high Wednesday after the generic drugmaker said new products and stronger sales will boost 2017 earnings.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.